Kiniksa Pharmaceuticals International Newsroom

J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $40

Futu NewsNov 5 20:31

Kiniksa Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group

Dow JonesOct 30 23:08

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaOct 30 22:58

Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35

Futu NewsOct 30 20:33

Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $35

Futu NewsOct 30 18:35

Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $35

Futu NewsOct 10 20:36

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaSep 13 21:05

Jefferies Initiates Kiniksa Pharmaceuticals at Buy With $40 Price Target

MT NewswiresSep 13 19:39

Jefferies Initiates Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Announces Target Price $40

Futu NewsSep 13 17:33

J.P. Morgan Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $39

Futu NewsSep 12 20:32

Evercore Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $30

Futu NewsJul 24 20:33

Wells Fargo Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Raises Target Price to $35

Futu NewsJul 24 17:32

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaJul 24 00:55

Goldman Sachs Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $32

Futu NewsJul 24 00:31

Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $34 From $30, Maintains Outperform Rating

MT NewswiresJul 23 22:33

Kiniksa Pharmaceuticals (KNSA.US) was covered for the first time by Wells Fargo, giving it an increase rating, with a target price of $34.00.

Zhitong FinanceMay 3 23:51

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaMay 3 23:50

Wells Fargo Initiates Coverage On Kiniksa Pharmaceuticals With Overweight Rating, Announces Price Target of $34

BenzingaMay 3 23:50

Komo: Maintaining the Kiniksa Pharmaceuticals (KNSA.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $26.00 to $30.00.

Zhitong FinanceMay 1 22:51

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaMay 1 22:50